Payel J Roy1, Melanie Weltman2, Laura M Dember3,4, Jane Liebschutz1, Manisha Jhamb5. 1. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine. 2. Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh. 3. Renal, Electrolyte and Hypertension Division, Department of Medicine. 4. Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia. 5. Division of Renal-Electrolyte, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: This review evaluates current recommendations for pain management in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) with a specific focus on evidence for opioid analgesia, including the partial agonist, buprenorphine. RECENT FINDINGS: Recent evidence supports the use of physical activity and other nonpharmacologic therapies, either alone or with pharmacological therapies, for pain management. Nonopioid analgesics, including acetaminophen, topical analgesics, gabapentinoids, serotonin-norepinephrine reuptake inhibitors, and TCA may be considered based on pain cause and type, with careful dose considerations in kidney disease. NSAIDs may be used in CKD and ESKD for short durations with careful monitoring. Opioid use should be minimized and reserved for patients who have failed other therapies. Opioids have been associated with increased adverse events in this population, and thus should be used cautiously after risk/benefit discussion with the patient. Opioids that are safer to use in kidney disease include oxycodone, hydromorphone, fentanyl, methadone, and buprenorphine. Buprenorphine appears to be a promising and safer option due to its partial agonism at the mu opioid receptor. SUMMARY: Pain is poorly managed in patients with kidney disease. Nonpharmacological and nonopioid analgesics should be first-line approaches for pain management. Opioid use should be minimized with careful monitoring and dose adjustment.
PURPOSE OF REVIEW: This review evaluates current recommendations for pain management in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) with a specific focus on evidence for opioid analgesia, including the partial agonist, buprenorphine. RECENT FINDINGS: Recent evidence supports the use of physical activity and other nonpharmacologic therapies, either alone or with pharmacological therapies, for pain management. Nonopioid analgesics, including acetaminophen, topical analgesics, gabapentinoids, serotonin-norepinephrine reuptake inhibitors, and TCA may be considered based on pain cause and type, with careful dose considerations in kidney disease. NSAIDs may be used in CKD and ESKD for short durations with careful monitoring. Opioid use should be minimized and reserved for patients who have failed other therapies. Opioids have been associated with increased adverse events in this population, and thus should be used cautiously after risk/benefit discussion with the patient. Opioids that are safer to use in kidney disease include oxycodone, hydromorphone, fentanyl, methadone, and buprenorphine. Buprenorphine appears to be a promising and safer option due to its partial agonism at the mu opioid receptor. SUMMARY: Pain is poorly managed in patients with kidney disease. Nonpharmacological and nonopioid analgesics should be first-line approaches for pain management. Opioid use should be minimized with careful monitoring and dose adjustment.
Authors: J A Lieberman; T B Cooper; R F Suckow; H Steinberg; M Borenstein; R Brenner; J M Kane Journal: Clin Pharmacol Ther Date: 1985-03 Impact factor: 6.875
Authors: Harald Breivik; Tone Marte Ljosaa; Kristian Stengaard-Pedersen; Jan Persson; Hannu Aro; John Villumsen; Dorthe Tvinnemose Journal: Scand J Pain Date: 2010-07-01
Authors: Hicham I Cheikh Hassan; Frank Brennan; Gemma Collett; Elizabeth A Josland; Mark A Brown Journal: J Pain Symptom Manage Date: 2014-09-08 Impact factor: 3.612
Authors: Ryan Perlman; Hili Giladi; Krista Brecht; Mark A Ware; Terence E Hebert; Lawrence Joseph; Yoram Shir Journal: Pain Date: 2013-08-20 Impact factor: 6.961
Authors: William C Becker; Michael J Fischer; Daniel G Tobin; Mark B Lockwood; Paul L Kimmel; Laura M Dember; Nwamaka D Eneanya; Manisha Jhamb; Thomas D Nolin Journal: Nat Rev Nephrol Date: 2021-10-07 Impact factor: 28.314
Authors: Sylwester Drożdżal; Kacper Lechowicz; Bartosz Szostak; Jakub Rosik; Katarzyna Kotfis; Anna Machoy-Mokrzyńska; Monika Białecka; Kazimierz Ciechanowski; Barbara Gawrońska-Szklarz Journal: Pharmacol Res Perspect Date: 2021-08